If you have been reading about Whey protein hydrolysate and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratories characterize whey protein hydrolysate using several complementary methods. Nitrogen determination estimates total protein, while size-exclusion chromatography and mass spectrometry reveal peptide size distributions. Degree of hydrolysis can be calculated from free amino groups, pH change, or osmolarity, but each approach has assumptions. Moisture, ash, and mineral content are also measured because they affect shelf life and reconstitution. No single test fully describes a hydrolysate, so specifications usually combine several results.
Storage stability depends on moisture, temperature, and exposure to oxygen. Dry hydrolysate powders are hygroscopic and can clump or cake when humidity is high. Moisture also promotes Maillard reactions between peptides and residual lactose, leading to browning and flavor changes. Cool, dry, sealed storage slows these reactions, while prolonged warmth can increase off-flavors and reduce solubility. Stability studies often track color, moisture, free amino groups, and microbial load over time to estimate shelf life.
Enzyme choice, pH, temperature, time, and substrate concentration influence the resulting peptide distribution. Endopeptidases cut internal peptide bonds, while exopeptidases remove terminal amino acids and can reduce bitterness. Manufacturers may combine enzymes or use membrane filtration to select peptide size ranges. A higher degree of hydrolysis generally means more small peptides and free amino acids, but it does not by itself define biological activity or nutritional quality. Batch-to-batch variation arises from raw whey composition, enzyme specificity, and processing parameters, so specification ranges are common in commercial supply.
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Moisture content | 3-7% typical | Lower moisture extends shelf life |
| pH (5% solution) | 6.0-7.5 | Varies with ash and processing |
| Storage condition | 15-25 °C, dry, sealed | Protect from humidity and odors |
| Common analytical method | Size-exclusion chromatography | Estimates peptide size distribution |
| Microbial limit | Typically <10^4 CFU/g | Product-specific and regional limits apply |
Laboratories characterize whey protein hydrolysate by several complementary methods. Total nitrogen or Kjeldahl analysis estimates crude protein, while amino acid analysis gives a more detailed composition. Size-exclusion chromatography and mass spectrometry separate peptides by molecular weight and can reveal the distribution of chain lengths. Degree of hydrolysis is often calculated from free amino groups using trinitrobenzenesulfonic acid or o-phthaldialdehyde assays. No single measurement captures all relevant properties, so specifications usually combine protein content, peptide profile, moisture, ash, and microbial limits.
Storage stability depends on moisture, temperature, oxygen, and packaging. Dry hydrolysate powders are typically stable for months to years when kept cool and sealed, but they can absorb water and cake if exposed to humid air. Higher temperatures accelerate Maillard reactions between peptides and residual sugars, leading to browning and flavor changes. Lipid oxidation can occur if residual fat is present, producing off-odors. Once a powder is reconstituted, microbial growth becomes a concern, so liquid forms require refrigeration or other preservation steps.
Quality control for hydrolysates often includes allergen and contaminant checks. Because whey is a milk-derived ingredient, milk protein residues may remain, and the extent to which hydrolysis reduces allergenic potential is product-specific and not fully predictable. Tests may screen for heavy metals, melamine, pesticides, and microbial indicators. Enzyme residues and processing aids are also monitored when regulations require it. Batch-to-batch consistency is assessed through peptide mapping or functional tests, since small process changes can alter taste, solubility, or nutritional performance.
Whey protein hydrolysate is a dairy ingredient produced when whey proteins are treated with proteolytic enzymes or, less commonly, acid or heat under controlled conditions. The treatment cleaves peptide bonds and yields shorter peptide chains than those found in intact whey protein. The starting material is usually sweet whey or acid whey from cheese manufacture, concentrated by membrane filtration before hydrolysis. The resulting ingredient retains many amino acids from the original protein but differs in molecular size, solubility, and taste profile.
The parent whey proteins include beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulins, and glycomacropeptide, depending on the whey source. Hydrolysis does not remove these sequences; it fragments them into peptides of varying length. The peptide distribution depends on the enzyme specificity, reaction time, temperature, pH, and enzyme-to-substrate ratio. Because the mixture is heterogeneous, a single molecular weight cannot describe the product. Instead, laboratories report a distribution, often spanning from a few hundred to several thousand daltons.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
=== Insect === The Drosophila melanogaster genome contains 29 serpin encoding genes. Amino acid sequence analysis has placed 14 of these serpins in serpin clade Q and three in serpin clade K with the remaining twelve classified as orphan serpins not belonging to any clade. The clade classification system is difficult to use for Drosophila serpins and instead a nomenclature system has been adopted that is based on the position of serpin genes on the Drosophila chromosomes. Thirteen of the Drosophila serpins occur as isolated genes in the genome (including Serpin-27A, see below), with the remaining 16 organised into five gene clusters that occur at chromosome positions 28D (2 serpins), 42D (5 serpins), 43A (4 serpins), 77B (3 serpins) and 88E (2 serpins). Studies on Drosophila serpins reveal that Serpin-27A inhibits the Easter protease (the final protease in the Nudel, Gastrulation Defective, Snake and Easter proteolytic cascade) and thus controls dorsoventral patterning. Easter functions to cleave Spätzle (a chemokine-type ligand), which results in toll-mediated signaling. As well as its central role in embryonic patterning, toll signaling is also important for the innate immune response in insects. Accordingly, serpin-27A also functions to control the insect immune response. In Tenebrio molitor (a large beetle), a protein (SPN93) comprising two discrete tandem serpin domains functions to regulate the toll proteolytic cascade. Serpins have been found in tick saliva, suppressing T lymphocyte production and inhibiting expression of TNF-α, IFN-γ, and IL-6.
Glomerular filtration of unbound drug. Active secretion of (free & protein-bound) drug by transporters (e.g. anions such as urate, penicillin, glucuronide, sulfate conjugates) or cations such as choline, histamine. Filtrate 100-fold concentrated in tubules for a favorable concentration gradient so that it may be secreted by passive diffusion and passed out through the urine.
Octodrine, also known as dimethylhexylamine (DMHA) and sold under the brand name Vaporpac among others, is a sympathomimetic and stimulant medication that was formerly used in the treatment of hypotension (low blood pressure). It has been studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the Food and Drug Administration (FDA) as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral medication as part of a multi-component medication (i.e., Ambredin and Ordinal), but is no longer available. DMHA has also been found as an adulterant in preworkout products and is also sold online as a designer drug. The presence of a reductive amination byproduct in seized samples confirms the drug is fully synthetic in origin. In the United States, the FDA considers DMHA to be an unsafe ingredient in dietary supplements. In 2019, the FDA issued nine warning letters to US manufacturers of dietary supplements containing DMHA as an unsafe food additive, deeming such products to be adulterated and illegal for marketing.
=== Draft and minor leagues === The Boston Red Sox selected Bagwell in the fourth round (110th overall) of the 1989 Major League Baseball draft. Throughout his career, Barry Axelrod served as his agent. For his first professional assignment, the Red Sox appointed Bagwell to the Single-A Winter Haven Red Sox of the Florida State League in 1989, where he batted .310 with two home runs. In 1990, while playing for the Double-A New Britain Red Sox, Bagwell won the Eastern League Most Valuable Player Award. In 136 games with New Britain, he batted .333 with 160 hits, four home runs (HR), 61 runs batted in (RBI), 34 doubles, seven triples, 73 bases on balls (BB or walks), 57 strikeouts (SO), .422 on-base percentage (OBP), .457 slugging percentage (SLG) and .880 on-base plus slugging percentage (OPS). He finished first in the league in hits and doubles, second in batting, OBP and OPS, fourth in walks, fifth in SLG, ninth in runs scored and tenth in RBI. Late in the 1990 season, the Red Sox, who were in search of relief pitching to improve their chances of making the playoffs, contacted the Houston Astros about Larry Andersen. Stan Benjamin, who scouted the New England region for the Astros, recommended that they ask for Bagwell in return. The Astros initially hesitated owing to his sparse home run production, but Benjamin persuaded them, quipping that New Britain's Beehive Field was so large that "Babe Ruth couldn't hit home runs in that ballpark."[a] On August 30, 1990, the Red Sox took the Astros' offer.
Sources: en.wikipedia.org
Absolute bioavailability compares the bioavailability of the active drug in systemic circulation following non-intravenous administration (i.e., after oral, buccal, ocular, nasal, rectal, transdermal, subcutaneous, or sublingual administration), with the bioavailability of the same drug following intravenous administration. It is the fraction of exposure to a drug (AUC) through non-intravenous administration compared with the corresponding intravenous administration of the same drug. The comparison must be dose normalized (e.g., account for different doses or varying weights of the subjects); consequently, the amount absorbed is corrected by dividing the corresponding dose administered. In pharmacology, in order to determine absolute bioavailability of a drug, a pharmacokinetic study must be done to obtain a plasma drug concentration vs time plot for the drug after both intravenous (iv) and extravascular (non-intravenous, i.e., oral) administration. The absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous. The formula for calculating the absolute bioavailability, F, of a drug administered orally (po) is given below (where D is dose administered).
==== Solid state ==== Few neptunium(III) coordination compounds are known, because Np(III) is readily oxidized by atmospheric oxygen while in aqueous solution. However, sodium formaldehyde sulfoxylate can reduce Np(IV) to Np(III), stabilizing the lower oxidation state and forming various sparingly soluble Np(III) coordination complexes, such as Np2(C2O4)3·11H2O, Np2(C6H5AsO3)3·H2O, and Np2[C6H4(OH)COO]3. Many neptunium(IV) coordination compounds have been reported, the first one being (Et4N)Np(NCS)8, which is isostructural with the analogous uranium(IV) coordination compound. Other Np(IV) coordination compounds are known, some involving other metals such as cobalt (CoNp2F10·8H2O, formed at 400 K) and copper (CuNp2F10·6H2O, formed at 600 K). Complex nitrate compounds are also known: the experimenters who produced them in 1986 and 1987 obtained single crystals by slow evaporation of the Np(IV) solution at ambient temperature in concentrated nitric acid and excess 2,2′-pyrimidine. The coordination chemistry of neptunium(V) has been extensively researched due to the presence of cation–cation interactions in the solid state, which had been already known for actinyl ions. Some known such compounds include the neptunyl dimer Na4(NpO4)2C12O12·8H2O and neptunium glycolate, both of which form green crystals. Neptunium(VI) compounds range from the simple oxalate NpO2C2O4 (which is unstable, usually becoming Np(IV)) to such complicated compounds as the green (NH4)4NpO2(CO3)3.
=== Pancreatitis and pancreatic cancer === An association of the DPP-IV inhibitor class with pancreatic problems has been proposed, mainly based on case reports associated with the DPP-IV inhibitor sitagliptin and several incretin mimetics including exenatide. A 2013 study of the DPP-4 inhibitor sitagliptin reported found "worrisome changes in the pancreases of the rats that could lead to pancreatic cancer". A second paper by the same authors reported an increase in precancerous lesions in the pancreases of organ donors who had taken GLP-1 inhibitors. In response to these reports, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-IV inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicines, the agencies stated that "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship.
Sources: en.wikipedia.org
Common methods quantify free amino groups, pH change, or osmolarity during or after hydrolysis. Each method uses different assumptions and can yield different values for the same sample. For this reason, degree of hydrolysis should be reported with the method used.
Hydrolysate powders attract moisture because short peptides and residual minerals are hygroscopic. High humidity causes particles to stick, cake, and sometimes dissolve partially. Sealed packaging with a moisture barrier reduces this problem.
Labeling rules vary by country and by product type. Some jurisdictions allow reduced-allergen claims only when clinical and analytical evidence supports them. Hydrolysis alone does not guarantee that a product is safe for people with milk allergy.
Hydrolysate has been enzymatically or chemically cleaved into smaller peptides, whereas isolate is largely intact protein that has been filtered to high protein content. The two can share a dairy origin but differ in peptide length, taste, and functional behavior. Degree of hydrolysis is a common but not standardized descriptor.